Halia Therapeutics
Tuesday, February 27, 2024
Plymouth
Inflammation
Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
State
Utah
Country
United States
Website
http://HaliaTx.com
CEO/Top Company Official
David Bearss
Lead Product in Development
Lead product is HT-6184
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
Three